Date: 2017-08-22
Type of information: Nomination
Compound: chief medical officer
Company: Atara Biotherapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On August 22, 2017, Atara Biotherapeutics announced the appointment of Kanya Rajangam as Senior Vice President and Chief Medical Officer. Dr. Rajangam brings to Atara extensive global oncology clinical development experience, including advancing multiple early- and late-stage programs. Dr. Rajangam joins Atara from Cleave Biosciences where she served as Chief Medical Officer, overseeing clinical development programs in hematologic and solid tumor malignancies. Previously, Dr. Rajangam was a Senior Medical Director at Onyx Pharmaceuticals, where she played a key role in the successful FDA and EMA submissions of the multiple myeloma product Kyprolis® (carfilzomib). Prior to this, Dr. Rajangam was Associate Medical Director at Exelixis, where she designed early-stage oncology clinical studies, including for Cometriq® (cabozantinib) and Cotellic® (cobimetinib). Throughout her career, Dr. Rajangam has worked closely with pharmaceutical partners including Amgen, Sanofi, BMS and Genentech to advance oncology programs in all phases of clinical development.
- After earning her medical degree from St. John's Medical College in Bangalore, India, Dr. Rajangam completed a surgical residency, including a master's thesis in renal transplantation, at the Postgraduate Institute of Medical Education and Research (India). She then earned her doctorate in biomedical tissue engineering from Northwestern University.
Financial terms:
Latest news:
Is general: Yes
